Global Blood Therapeutics Inc (NASDAQ:GBT) major shareholder Perceptive Advisors Llc acquired 175,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 19th. The shares were acquired at an average price of $38.00 per share, with a total value of $6,650,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Shares of Global Blood Therapeutics Inc (NASDAQ GBT) traded down $0.85 on Tuesday, reaching $35.95. The company’s stock had a trading volume of 996,774 shares, compared to its average volume of 1,041,675. Global Blood Therapeutics Inc has a fifty-two week low of $13.35 and a fifty-two week high of $45.85.

Global Blood Therapeutics (NASDAQ:GBT) last issued its earnings results on Thursday, November 2nd. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.04). During the same period last year, the business earned ($0.58) earnings per share. equities analysts forecast that Global Blood Therapeutics Inc will post -2.55 earnings per share for the current year.

Several brokerages recently weighed in on GBT. Oppenheimer set a $53.00 price objective on Global Blood Therapeutics and gave the stock a “buy” rating in a research report on Monday, October 30th. Cantor Fitzgerald set a $61.00 price objective on Global Blood Therapeutics and gave the stock a “buy” rating in a research report on Monday, December 11th. J P Morgan Chase & Co restated a “buy” rating on shares of Global Blood Therapeutics in a research report on Monday, October 23rd. BidaskClub downgraded Global Blood Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, September 14th. Finally, Zacks Investment Research raised Global Blood Therapeutics from a “hold” rating to a “buy” rating and set a $36.00 target price for the company in a report on Tuesday, October 10th. One analyst has rated the stock with a sell rating, one has given a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Global Blood Therapeutics presently has a consensus rating of “Buy” and an average price target of $62.07.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Perceptive Advisors LLC increased its stake in shares of Global Blood Therapeutics by 8.4% in the third quarter. Perceptive Advisors LLC now owns 4,264,066 shares of the company’s stock valued at $132,399,000 after buying an additional 330,139 shares during the period. BlackRock Inc. increased its stake in shares of Global Blood Therapeutics by 30.0% in the second quarter. BlackRock Inc. now owns 3,404,538 shares of the company’s stock valued at $93,114,000 after buying an additional 785,691 shares during the period. Vanguard Group Inc. increased its stake in shares of Global Blood Therapeutics by 15.7% in the second quarter. Vanguard Group Inc. now owns 2,933,251 shares of the company’s stock valued at $80,224,000 after buying an additional 397,271 shares during the period. Orbimed Advisors LLC increased its stake in shares of Global Blood Therapeutics by 10.2% in the third quarter. Orbimed Advisors LLC now owns 2,393,635 shares of the company’s stock valued at $74,322,000 after buying an additional 221,700 shares during the period. Finally, State Street Corp increased its stake in shares of Global Blood Therapeutics by 217.9% in the second quarter. State Street Corp now owns 2,138,323 shares of the company’s stock valued at $58,479,000 after buying an additional 1,465,595 shares during the period. 90.25% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This report was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://www.watchlistnews.com/perceptive-advisors-llc-purchases-175000-shares-of-global-blood-therapeutics-inc-gbt-stock/1773562.html.

Global Blood Therapeutics Company Profile

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Insider Buying and Selling by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.